Introduction Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). Case report Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests. Conclusion CP might be an effective therapy for severe COVID-19 patients. Highlights • Currently, no specific antiviral drug has been approved to target novel coronavirus. • Convalescent plasma is a classical immunotherapy. • It has been used in the management of several infectious diseases for many decades. • In this report two severe cases of COVID-2019 have been described receiving CP.
【저자키워드】 COVID-19, convalescent plasma, SARS-CoV-2, coronavirus, 【초록키워드】 antiviral therapy, severe COVID-19, Immunotherapy, Infectious disease, antiviral drug, Novel coronavirus, COVID-2019, Medicine, 2019 novel coronavirus, management, male, Research, Patient, plasma, disease, supportive care, severe COVID-19 patients, Severe case, effective therapy, CP infusion, IMPROVE, described, classical, clinically, diagnosed, approved, receiving, discharged, 【제목키워드】 convalescent, COVID-19 patient, case sery,